Elevation Oncology ELEV Stock
Elevation Oncology Price Chart
Elevation Oncology ELEV Financial and Trading Overview
| Elevation Oncology stock price | 4.01 USD |
| Previous Close | 1.53 USD |
| Open | 1.53 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 4000 |
| Day's Range | 1.43 - 1.53 USD |
| 52 Week Range | 0.72 - 5.89 USD |
| Volume | 1.09M USD |
| Avg. Volume | 1.96M USD |
| Market Cap | 36.02M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.34 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.17 USD |
ELEV Valuation Measures
| Enterprise Value | -7098131 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.9308176 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.0422536 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.08 |
Trading Information
Elevation Oncology Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 12.97% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.89 USD |
| 52 Week Low | 0.72 USD |
| 50-Day Moving Average | 2.9 USD |
| 200-Day Moving Average | 1.6 USD |
ELEV Share Statistics
| Avg. Volume (3 month) | 1.96M USD |
| Avg. Daily Volume (10-Days) | 2.06M USD |
| Shares Outstanding | 24.34M |
| Float | 16.86M |
| Short Ratio | 0.72 |
| % Held by Insiders | 2.14% |
| % Held by Institutions | 74.24% |
| Shares Short | 2.57M |
| Short % of Float | 13.23% |
| Short % of Shares Outstanding | 10.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -52.56% |
| Return on Equity (ttm) | -120.36% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -88790336 USD |
| Net Income Avi to Common (ttm) | -94864000 USD |
| Diluted EPS (ttm) | -3.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 73.93M USD |
| Total Cash Per Share (mrq) | 3.04 USD |
| Total Debt (mrq) | 29.6M USD |
| Total Debt/Equity (mrq) | 87.67 USD |
| Current Ratio (mrq) | 5.603 |
| Book Value Per Share (mrq) | 1.42 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -88290000 USD |
| Levered Free Cash Flow (ttm) | -48141876 USD |
Profile of Elevation Oncology
| Country | United States |
| State | NY |
| City | New York |
| Address | 888 Seventh Avenue |
| ZIP | 10106 |
| Phone | 716 371 1125 |
| Website | https://elevationoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 33 |
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.
Q&A For Elevation Oncology Stock
What is a current ELEV stock price?
Elevation Oncology ELEV stock price today per share is 4.01 USD.
How to purchase Elevation Oncology stock?
You can buy ELEV shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Elevation Oncology?
The stock symbol or ticker of Elevation Oncology is ELEV.
Which industry does the Elevation Oncology company belong to?
The Elevation Oncology industry is Biotechnology.
How many shares does Elevation Oncology have in circulation?
The max supply of Elevation Oncology shares is 57.39M.
What is Elevation Oncology Price to Earnings Ratio (PE Ratio)?
Elevation Oncology PE Ratio is now.
What was Elevation Oncology earnings per share over the trailing 12 months (TTM)?
Elevation Oncology EPS is -1.34 USD over the trailing 12 months.
Which sector does the Elevation Oncology company belong to?
The Elevation Oncology sector is Healthcare.
Elevation Oncology ELEV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}